Forest Laboratories, Inc. (FRX) and Gedeon Richter Ltd. Announce Results from a Phase II Study of Cariprazine as Adjunctive Therapy in Major Depressive Disorder
2/28/2011 9:04:17 AM
NEW YORK & BUDAPEST, Hungary--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc. today announced preliminary top-line results from an 8-week Phase II clinical trial of the novel, investigational antipsychotic agent cariprazine as adjunctive therapy in major depressive disorder. Cariprazine is currently undergoing Phase III trials for the separate and additional indications of schizophrenia and bipolar mania.
comments powered by